← Back to Search

Phosphodiesterase-4 (PDE-4) Inhibitor

Crisaborole for Atopic Dermatitis

Phase 4
Waitlist Available
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at days 1, 8,15, 21 and 29
Awards & highlights

Study Summary

The purpose of this study is to document the timing of improvement in atopic dermatitis symptoms and severity following the application of crisaborole ointment 2% in patients 2 years or older with mild to moderate atopic dermatitis. Crisaborole ointment 2% will be applied topically twice daily for four weeks and progress will be assessed by photography and patient-reports.

Eligible Conditions
  • Atopic Dermatitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at days 1, 8,15, 21 and 29
This trial's timeline: 3 weeks for screening, Varies for treatment, and at days 1, 8,15, 21 and 29 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Time to success (by week) on ISGA
Time to success (in days) on ISGA

Trial Design

1Treatment groups
Experimental Treatment
Group I: CrisaboroleExperimental Treatment1 Intervention
Crisaborole is a low molecular weight benzoxaborole PDE-4 inhibitor for the treatment of mild-to-moderate atopic dermatitis in adults and children 2 years and above. Crisaborole ointment 2% is topically applied as a thin layer twice daily for 4 weeks to all AD lesions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Crisaborole
FDA approved

Find a Location

Who is running the clinical trial?

PfizerIndustry Sponsor
4,570 Previous Clinical Trials
10,910,290 Total Patients Enrolled
Massachusetts General HospitalLead Sponsor
2,932 Previous Clinical Trials
13,198,340 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Journal of the American Academy of DermatologyJournal
Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults
Paller, Amy S., Wynnis L. Tom, Mark G. Lebwohl, Robin L. Blumenthal, Mark Boguniewicz, Robert S. Call, Lawrence F. Eichenfield, et al.. 2016. “Efficacy and Safety of Crisaborole Ointment, a Novel, Nonsteroidal Phosphodiesterase 4 (PDE4) Inhibitor for the Topical Treatment of Atopic Dermatitis (AD) in Children and Adults”. Journal of the American Academy of Dermatology. Elsevier BV. doi:10.1016/j.jaad.2016.05.046.
Clinical and Experimental DermatologyJournal
Dermatology Life Quality Index (dlqi)-a Simple Practical Measure for Routine Clinical Use
FINLAY, A.Y., and G.K. KHAN. 1994. “Dermatology Life Quality Index (dlqi)-a Simple Practical Measure for Routine Clinical Use”. Clinical and Experimental Dermatology. Wiley. doi:10.1111/j.1365-2230.1994.tb01167.x.
clinicaltrials.govStudy
Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis
Gideon Piers Smith 2020. "Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04214197.
All > Seborrheic Dermatitis > Atopic Dermatitis
~29 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top